Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report

OBJECTIVE: ROS1 fusions have been identified in 1–2% of non-small-cell lung cancer (NSCLC) patients; they are validated as a driver of carcinogenesis and could be subjected to inhibition by crizotinib. However, previous studies suggested a variable progression-free survival (PFS) ranging from 9.1 to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Shu, Yun, Li, Hui, Shang, Hongjuan, Chen, Jun, Su, Xiaoxing, Le, Wei, Lei, Yan, Tao, Liming, Zou, Cailiang, Wu, Wendy
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2020
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7568639/
https://ncbi.nlm.nih.gov/pubmed/33116618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S270961
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky